Exosomes: Emerging biomarkers and targets for ovarian cancer

Cancer Letters

Volumn 367, Issue 1, 2015, Pages 26-33

  Tang, Maggie K S ^a   Wong, Alice S T ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Exosomes; Ovarian cancer; Protein; RNA

Indexed keywords

BIOLOGICAL MARKER; CURCUMIN; RAB PROTEIN; RAB27A PROTEIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL COMMUNICATION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOTHELIUM CELL; EXOSOME; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCOMPETENT CELL; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; SHORT SURVEY; STROMA CELL; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; ANIMAL; DRUG DESIGN; DRUG EFFECTS; FEMALE; METABOLISM; OVARIAN NEOPLASMS; PARACRINE SIGNALING; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; EXOSOMES; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PARACRINE COMMUNICATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84939269936     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.014     Document Type: Review

References (69)

1. Pan B.T., Johnstone R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33:967-978.
2. Johnstone R.M., Adam M., Hammond J.R., Orr L., Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem 1987, 262:9412-9420.
3. Théry C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol. Rep 2011, 3:15.
4. Théry C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol 2009, 9:581-593.
5. Parolini I., Federici C., Raggi C., Lugini L., Palleschi S., De Milito A., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem 2009, 284:34211-34222.
6. Morelli A.E., Larregina A.T., Shufesky W.J., Sullivan M.L., Stolz D.B., Papworth G.D., et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004, 104:3257-3266.
7. Christianson H.C., Svensson K.J., van Kuppevelt T.H., Li J.P., Belting M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:17380-17385.
8. Svensson K.J., Christianson H.C., Wittrup A., Bourseau-Guilmain E., Lindqvist E., Svensson L.M., et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. J. Biol. Chem 2013, 288:17713-17724.
9. Bretz N.P., Ridinger J., Rupp A.K., Rimbach K., Keller S., Rupp C., et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J. Biol. Chem 2013, 288:36691-36702.
10. Battke C., Ruiss R., Welsch U., Wimberger P., Lang S., Jochum S., et al. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol. Immunother 2011, 60:639-648.
11. Peng P., Yan Y., Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol. Rep 2011, 25:749-762.
12. Stack M.S., Fishman D.A. Ovarian Cancer. Cancer Treatment and Research 2010, vol. 149. Springer., US.
13. Le Pecq J.B. Dexosomes as a therapeutic cancer vaccine: from bench to bedside. Blood Cells Mol. Dis 2005, 35:129-135.
14. Patel S., Mehta-Damani A., Shu H., Le Pecq J.B. An analysis of variability in the manufacturing of dexosomes: implications for development of an autologous therapy. Biotechnol. Bioeng 2005, 92:238-249.
15. Morello M., Minciacchi V.R., de Candia P., Yang J., Posadas E., Kim H., et al. Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle 2013, 12:3526-3536.
16. Di Vizio D., Kim J., Hager M.H., Morello M., Yang W., Lafargue C.J., et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009, 69:5601-5609.
17. Tauro B.J., Greening D.W., Mathias R.A., Mathivanan S., Ji H., Simpson R.J. Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. Mol. Cell. Proteomics 2013, 12:587-598.
18. Simpson R.J., Kalra H., Mathivanan S. ExoCarta as a resource for exosomal research. J. Extracell. Vesicles 2012, 1.
19. Szajnik M., Czystowska M., Szczepanski M.J., Mandapathil M., Whiteside T.L. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 2010, 5:e11469.
20. Runz S., Keller S., Rupp C., Stoeck A., Issa Y., Koensgen D., et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol. Oncol 2007, 107:563-571.
21. Stoeck A., Keller S., Riedle S., Sanderson M.P., Runz S., Le Naour F., et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem. J. 2006, 393:609-618.
22. Liang B., Peng P., Chen S., Li L., Zhang M., Cao D., et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J. Proteomics 2013, 80:171-182.
23. Escrevente C., Grammel N., Kandzia S., Zeiser J., Tranfield E.M., Conradt H.S., et al. Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells. PLoS ONE 2013, 8:e78631.
24. Gutwein P., Mechtersheimer S., Riedle S., Stoeck A., Gast D., Joumaa S., et al. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J. 2003, 17:292-294.
25. Lee H.D., Kim Y.H., Koo B.H., Kim D.S. Ectodomain of ADAM15 is shed from secretory exosomes. BMB Rep 2014, pii: 2901.
26. Keller S., König A.K., Marmé F., Runz S., Wolterink S., Koensgen D., et al. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett 2009, 278:73-81.
27. Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002, 360:295-305.
28. Bard M.P., Hegmans J.P., Hemmes A., Luider T.M., Willemsen R., Severijnen L.A., et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Respir. Cell Mol. Biol 2004, 31:114-121.
29. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol 2008, 110:13-21.
30. Kobayashi M., Salomon C., Tapia J., Illanes S.E., Mitchell M.D., Rice G.E. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J. Transl. Med 2014, 12:4.
31. Ge R., Tan E., Sharghi-Namini S., Asada H.H. Exosomes in cancer microenvironment and beyond: have we overlooked these extracellular messengers?. Cancer Microenviron 2012, 5:323-332.
32. Beach A., Zhang H.G., Ratajczak M.Z., Kakar S.S. Exosomes: an overview of biogenesis, composition and role in ovarian cancer. J. Ovarian Res 2014, 7:14.
33. Pink R.C., Samuel P., Massa D., Caley D.P., Brooks S.A., Carter D.R. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol. Oncol 2015, 137:143-151.
34. Vaksman O., Tropé C., Davidson B., Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 2014, 35:2113-2120.
35. Szajnik M., Derbis M., Lach M., Patalas P., Michalak M., Drzewiecka H., et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy. Gynecol. Obstet. (Sunnyvale) 2013, 3(Suppl. 4).
36. Yin J., Yan X., Yao X., Zhang Y., Shan Y., Mao N., et al. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J. Cell. Mol. Med 2012, 16:337-348.
37. Cho J.A., Park H., Lim E.H., Kim K.H., Choi J.S., Lee J.H., et al. Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol 2011, 123:379-386.
38. Gutwein P., Stoeck A., Riedle S., Gast D., Runz S., Condon T.P., et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin. Cancer Res 2005, 11:2492-2501.
39. Safaei R., Larson B.J., Cheng T.C., Gibson M.A., Otani S., Naerdemann W. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther 2005, 4:1595-1604.
40. Taylor D.D., Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer 2005, 92:305-311.
41. Peinado H., Alečković M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med 2012, 18:883-891.
42. Lis R., Touboul C., Raynaud C.M., Malek J.A., Suhre K., Mirshahi M., et al. Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. PLoS ONE 2012, 7:e38340.
43. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
44. Umezu T., Ohyashiki K., Kuroda M., Ohyashiki J.H. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 2013, 32:2747-2755.
45. Kucharzewska P., Christianson H.C., Welch J.E., Svensson K.J., Fredlund E., Ringnér M., et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7312-7317.
46. Zhang B., Cai F.F., Zhong X.Y. An overview of biomarkers for the ovarian cancer diagnosis. Eur. J. Obstet. Gynecol. Reprod. Biol 2011, 158:119-123.
47. Partridge E.E., Greenlee R.T., Riley T.L., Commins J., Ragard L., Xu J.L., et al. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. Obstet. Gynecol 2013, 121:25-31.
48. Li J., Sherman-Baust C.A., Tsai-Turton M., Bristow R.E., Roden R.B., Morin P.J. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 2009, 9:244.
49. Im H., Shao H., Park Y.I., Peterson V.M., Castro C.M., Weissleder R., et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat. Biotechnol 2014, 32:490-495.
50. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
51. Melo S.A., Sugimoto H., O'Connell J.T., Kato N., Villanueva A., Vidal A., et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 2014, 26:707-721.
52. Peterson M.F., Otoc N., Sethi J.K., Gupta A., Antes T.J. Integrated systems for exosome investigation. Methods 2015, pii: S1046-2023(15)00161-00169. [Epub ahead of print].
53. Böing A.N., van der Pol E., Grootemaat A.E., Coumans F.A., Sturk A., Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J. Extracell. Vesicles 2014, 3.
54. Liga A., Vliegenthart A.D., Oosthuyzen W., Dear J.W., Kersaudy-Kerhoas M. Exosome isolation: a microfluidic road-map. Lab Chip 2015, 15:2388-2394.
55. Chen C., Skog J., Hsu C.H., Lessard R.T., Balaj L., Wurdinger T., et al. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 2010, 10:505-511.
56. Davies R.T., Kim J., Jang S.C., Choi E.J., Gho Y.S., Park J. Microfluidic filtration system to isolate extracellular vesicles from blood. Lab Chip 2012, 12:5202-5210.
57. He M., Crow J., Roth M., Zeng Y., Godwin A.K. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip 2014, 14:3773-3780.
58. Rho J., Chung J., Im H., Liong M., Shao H., Castro C.M., et al. Magnetic nanosensor for detection and profiling of erythrocyte-derived microvesicles. ACS Nano 2013, 7:11227-11233.
59. Marleau A.M., Chen C.S., Joyce J.A., Tullis R.H. Exosome removal as a therapeutic adjuvant in cancer. J. Transl. Med 2012, 10:134.
60. Hurley J.H., Odorizzi G. Get on the exosome bus with ALIX. Nat. Cell Biol 2012, 14:654-655.
61. Kandalaft L.E., Motz G.T., Duraiswamy J., Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011, 30:141-151.
62. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med 1996, 183:1161-1172.
63. Escudier B., Dorval T., Chaput N., André F., Caby M.P., Novault S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J. Transl. Med 2005, 3:10.
64. Morse M.A., Garst J., Osada T., Khan S., Hobeika A., Clay T.M., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med 2005, 3:9.
65. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med 2003, 348:203-213.
66. Navabi H., Croston D., Hobot J., Clayton A., Zitvogel L., Jasani B., et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol. Dis 2005, 35:149-152.
67. Sun D., Zhuang X., Xiang X., Liu Y., Zhang S., Liu C., et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther 2010, 18:1606-1614.
68. Ju S., Mu J., Dokland T., Zhuang X., Wang Q., Jiang H., et al. Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol. Ther 2013, 21:1345-1357.
69. Cai Y.Y., Lin W.P., Li A.P., Xu J.Y. Combined effects of curcumin and triptolide on an ovarian cancer cell line. Asian Pac. J. Cancer Prev 2013, 14:4267-4271.